Search results for "Infusion"

showing 10 items of 233 documents

Listeria phage and phage tail induction triggered by components of bacterial-growth media (phosphate, LiCl, nalidixic acid and acriflavine)

2015

ABSTRACT The detection of Listeria monocytogenes from food is currently carried out using a double enrichment. For the ISO methodology, this double enrichment is performed using half-Fraser and Fraser broths, in which the overgrowth of L. innocua can occur in samples where both species are present. In this study, we analyzed the induction of phages and phage tails of Listeria spp. in these media and in two brain heart infusion (BHI) broths (BHIM [bioMérieux] and BHIK [Biokar]) to identify putative effectors. It appears that Na 2 HPO 4 at concentrations ranging from 1 to 40 g/liter with an initial pH of 7.5 can induce phage or phage tail production of Listeria spp., especially with 10 g/lite…

Nalidixic acidListeriaviruses[SDV]Life Sciences [q-bio]Bacterial growthmedicine.disease_causeApplied Microbiology and BiotechnologyacriflavineMicrobiologyPhosphateschemistry.chemical_compoundListeria sppListeria monocytogenesmedicinephage[SDV.BV]Life Sciences [q-bio]/Vegetal BiologyBacteriophagesLiClinductionphosphate2. Zero hungerEcologybiologynalidixic acidViral Tail ProteinsViral Tail Proteinsbiology.organism_classificationPhosphateCulture Mediachemistry[SDE]Environmental SciencesListeriaBrain heart infusionFood MicrobiologyAcriflavineVirus ActivationLithium ChlorideFood ScienceBiotechnologymedicine.drug
researchProduct

Imaging Findings in Non-Cirrhotic Liver

2011

With the widespread use of cross-sectional imaging examinations, physicians from a wide array of specialties are becoming involved with questions regarding the management of patients with focal liver lesions. To formulate a practical approach to these patients, several factors must be incorporated into a clinical decision-making algorithm, including the clinical setting (e.g., known comorbidities, underlying cirrhosis or a known primary neoplasm), the presence of clinical signs and symptoms, the results of laboratory tests, and the critical information provided by imaging studies. In this chapter, we will briefly review important technical factors for optimization of CT protocols for the ev…

Non cirrhotic livermedicine.medical_specialtyCirrhosisbusiness.industryFocal nodular hyperplasiaSigns and symptomsKey featuresmedicine.diseasePrimary NeoplasmHepatic arterial infusion chemotherapymedicineCentral ScarRadiologybusiness
researchProduct

Minimally invasive secondary cytoreduction plus HIPEC for recurrent ovarian cancer: a case series.

2014

Objective To analyze the feasibility of laparoscopic/robotic secondary cytoreductive surgery and hyperthermic intraperitoneal intra-operative chemotherapy (SCS + HIPEC) in a retrospective series of isolated platinum sensitive recurrent ovarian cancer. Methods We retrospectively evaluated a consecutive series of ovarian cancer patients with isolated platinum sensitive relapse. Isolated relapse was defined as the presence of a single nodule, in a single anatomic site. In all cases the presence of isolated relapse was assessed at pre-operative FDG-PET/CT scan, and confirmed with staging laparoscopy performed immediately before SCS + HIPEC. Results 84 women with platinum sensitive relapse recei…

OVARIAN CANEROrganoplatinum Compoundsmedicine.medical_treatmentdrug therapy/pathology/surgery/therapyCarcinoma Ovarian EpithelialMultimodal ImagingCohort StudiesObstetrics and gynaecologyNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsInfusions ParenteralNeoplasms Glandular and EpithelialLaparoscopyadministration /&/ dosageTomographyRandomized Controlled Trials as TopicOvarian Neoplasmsmedicine.diagnostic_testObstetrics and GynecologyGlandular and EpithelialMiddle AgedDebulkingCombined Modality TherapyIsolated platinum sensitive relapseX-Ray ComputedOxaliplatinPhase III as TopicOncologyFemalediagnostic usemedicine.drugmedicine.medical_specialtyInfusionsAged Antineoplastic Combined Chemotherapy Protocols; administration /&/ dosage Cisplatin; administration /&/ dosage Clinical Trials; Phase II as Topic Clinical Trials; Phase III as Topic Cohort Studies Combined Modality Therapy Female Fluorodeoxyglucose F18; diagnostic use Humans Hyperthermia; Induced; methods Infusions; Parenteral Middle Aged Minimally Invasive Surgical Procedures Multimodal Imaging Neoplasms; Glandular and Epithelial; drug therapy/pathology/surgery/therapy Organoplatinum Compounds; administration /&/ dosage Ovarian Neoplasms; drug therapy/pathology/surgery/therapy Positron-Emission Tomography Radiopharmaceuticals; diagnostic use Randomized Controlled Trials as Topic Retrospective Studies Tomography; X-Ray Computed ocal; pathologyocalmethodsClinical Trials Phase II as TopicMinimally invasive surgeryOvarian cancerFluorodeoxyglucose F18ParenteralmedicineHumansMinimally Invasive Surgical ProceduresClinical TrialsHyperthermiaAgedRetrospective StudiesCisplatinChemotherapySeries (stratigraphy)HIPECbusiness.industryPhase II as TopicInducedHyperthermia Inducedmedicine.diseaseOxaliplatinSurgeryRoboticSettore MED/40 - GINECOLOGIA E OSTETRICIAClinical Trials Phase III as TopicPositron-Emission TomographyLaparoscopypathologyNeoplasm Recurrence LocalCisplatinRadiopharmaceuticalsbusinessOvarian cancerTomography X-Ray Computed
researchProduct

Treatment of metastatic breast cancer with vinorelbine and docetaxel.

2006

Objective: A phase II study was performed to evaluate efficacy and safety of the combination vinorelbine and docetaxel in patients with metastatic breast cancer previously treated with anthracycline-based regimens. Overall 41 patients were included in the study. Methods: Treatment consisted of vinorelbine 25 mg/m 2 and docetaxel 75 mg/m 2 , both administered on day 1 every 3 weeks for a maximum of 9 cycles. Most patients (92%) were postmenopausal with a median age of 57 years, and median ECOG performance of 1. Sites of disease were viscera in 42% of patients, bones in 30%, soft-tissues in 32%. Sixty-five percent of patients had >2 metastatic sites. Previous treatments included neo-adjuvant …

OncologyAdultCancer Researchmedicine.medical_specialtyDocetaxel; Metastatic breast cancer; VinorelbineAnthracyclinemedicine.medical_treatmentPhases of clinical researchBreast NeoplasmsDocetaxelNeutropeniaVinorelbineVinblastineGastroenterologyInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMucositisMedicineHumansInfusions IntravenousChemotherapybusiness.industryVinorelbineMiddle Agedmedicine.diseaseMetastatic breast cancerMetastatic breast cancerSurvival AnalysisTreatment OutcomeOncologyDocetaxelDisease ProgressionFemaleTaxoidsbusinessmedicine.drugAmerican journal of clinical oncology
researchProduct

Oral chemotherapy and patient perspective in solid tumors: a national survey by the Italian association of medical oncology.

2015

Aim To assess patient perception toward oral chemotherapy for solid tumors, the Italian Association of Medical Oncology performed a large multi-institutional national survey. Methods A 17-item anonymous questionnaire including 7 general and 10 investigational questions with free-text, single-choice, or multiple-choice answers was administered. Analysis of response distribution according to predefined factors was described by summary measures and conducted by χ2 test and other nonparametric tests. Results From January to June 2010, 581 patients completed the questionnaire; data of 404 patients constituted the final study sample. Three groups could be distinguished according to treatment: IV …

OncologyAdultMaleCancer Researchmedicine.medical_specialtyOral chemotherapyAdministration OralWork commitment03 medical and health sciences0302 clinical medicineInternal medicineNeoplasmsSurveys and QuestionnairesAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansImpact on family030212 general & internal medicineInfusions IntravenousOral therapyAgedbusiness.industryIntravenous chemotherapyGeneral MedicineMiddle AgedPatient perceptionsOncologyItaly030220 oncology & carcinogenesisQuality of LifeCombined therapyFemalebusinessTumori
researchProduct

Phase II study of weekly docetaxel in patients with recurrent or metastatic endometrial cancer: AGO Uterus-4.

2006

Abstract Objective The aim of this phase II multicenter study was to evaluate the safety, toxicity and efficacy of docetaxel administered weekly as first line chemotherapy in patients with recurrent or metastatic endometrial cancer. Patients and methods Thirty five patients with recurrent or metastatic endometrial cancer without previous chemotherapy were enrolled to receive three 6-week cycles of docetaxel 35 mg/m 2 /week with 2-week breaks between the cycles. Therapy response was evaluated after every 6-week cycle, and therapy was continued in case of at least stable disease. Final therapy response was evaluated after three 6-week cycles of docetaxel. Results Thirty five patients with a m…

OncologyAdultmedicine.medical_specialtymedicine.medical_treatmentPhases of clinical researchAntineoplastic AgentsDocetaxelDrug Administration Schedule03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansNeoplasm MetastasisInfusions Intravenous030304 developmental biologyAgedAged 80 and over0303 health sciencesChemotherapybusiness.industryEndometrial cancerObstetrics and GynecologyCancerCombination chemotherapyMiddle Agedmedicine.disease3. Good healthEndometrial NeoplasmsClinical trialOncologyDocetaxel030220 oncology & carcinogenesisToxicityFemaleTaxoidsNeoplasm Recurrence Localbusinessmedicine.drugGynecologic oncology
researchProduct

Management of Toxicity Induced by Anti-EGFR Therapy in Metastatic Colorectal Cancer

2013

Use of anti-epidermal growth factor receptor (anti-EGFR) agents has yielded significant advances in the treatment of patients with metastatic colorectal cancer. In fact these drugs, which include the monoclonal antibodies cetuximab and panitumumab, can be delivered both as a single agent and in combination with chemotherapy, achieving better survival and quality of life and in some cases also resectability of metastases. However, these agents can result in the development of toxicities that are usually different from those observed with chemotherapy alone. For the management of these adverse effects, proper knowledge is mandatory. Skin toxicity is the most frequent adverse effect. Other tox…

OncologyColorectal cancerSettore MED/06 - Oncologia Medicamedicine.medical_treatmentPulmonary FibrosisCetuximabPharmacologyPrurituMagnesiumEpidermal growth factor receptorParonychiaCancerSkinbiologyCetuximabPanitumumabGastroenterologyfood and beveragesCutaneouOncologyToxicityMetastaticmedicine.drugDiarrheamedicine.medical_specialtyGastrointestinalAnti-epidermal growth factor receptorColonReactionInternal medicineRashmedicinePanitumumabToxicity; Epidermal growth factor receptor; Anti-epidermal growth factor receptor; Cetuximab; Panitumumab; Antibody; Metastatic; Colon; Rectum; Cancer; Treatment; Skin; Rash; Cutaneous; Pruritus; Xerosis; Paronychia; Hypomagnesemia; Magnesium; Gastrointestinal; Diarrhea; Infusion; Reaction; Pulmonary FibrosisInfusionAdverse effectAntibodyXerosisChemotherapyHepatologyToxicitybusiness.industryEpidermal growth factor receptorPruritusRectumCancermedicine.diseaseXerosiTreatmentCutaneousbiology.proteinHypomagnesemiabusiness
researchProduct

Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyur…

1996

BACKGROUND To date there is no established chemotherapeutic treatment for patients with unresectable locally advanced and/or metastatic carcinomas of the exocrine pancreas or the gallbladder. A multicenter Phase II trial has been performed by the Southern Italy Oncology Group with the aim of evaluating the clinical effectiveness and tolerability of weekly 5-fluorouracil (5-FU) in modulation with intravenous (i.v.) high dose levofolinic acid and oral hydroxyurea. METHODS A total of 70 patients fulfilling the standard eligibility for a Phase II study were enrolled in the trial. Forty patients had advanced pancreatic adenocarcinoma and 30 had advanced gallbladder carcinoma. The treatment sched…

OncologyMaleCancer Researchmedicine.medical_specialtyAntimetabolites AntineoplasticPancreatic diseaseAntidotesLeucovorinPhases of clinical researchAdministration OralAntineoplastic AgentsAdenocarcinomaGastroenterologyDrug Administration ScheduleMetastatic carcinomaInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansHydroxyureaInfusions IntravenousAgedbusiness.industryGallbladderCarcinomaRemission InductionLeukopeniaMiddle Agedmedicine.diseasePancreatic NeoplasmsSurvival Ratemedicine.anatomical_structureOncologyTolerabilityItalyInjections IntravenousDisease ProgressionAdenocarcinomaFemaleGallbladder NeoplasmsFluorouracilbusinessProgressive diseaseCancer
researchProduct

Hepatic arterial infusion of gemcitabine-oxaliplatin in a large metastasis from colon cancer

2010

International audience; Hepatic arterial infusion (HAI) of chemotherapy can be performed in cases of liver-confined metastatic disease, resulting in increased local drug concentrations. Here we report the case of a 61-year-old man who presented with an isolated large unresectable liver metastasis of colon cancer after failure of surgery and multiple administration of systemic chemotherapy. The patient was treated with a combination of gemcitabine and oxaliplatin using HAI. The tolerance was excellent and a radiological complete response was obtained after 8 cycles of HAI. The rationale for the use of gemcitabine and oxaliplatin as well as that for the combination of the 2 drugs is discussed…

OncologyMale[SDV.MHEP.CHI] Life Sciences [q-bio]/Human health and pathology/SurgeryOrganoplatinum CompoundsColorectal cancermedicine.medical_treatmentCase ReportDeoxycytidineMetastasischemistry.chemical_compound0302 clinical medicineHepatic ArteryAntineoplastic Combined Chemotherapy Protocols[ SDV.MHEP.CHI ] Life Sciences [q-bio]/Human health and pathology/Surgery0303 health sciencesLiver NeoplasmsGastroenterologyvirus diseasesGeneral MedicineMiddle AgedMagnetic Resonance Imaging3. Good healthOxaliplatinTreatment Outcome030220 oncology & carcinogenesisColonic NeoplasmsCatheter AblationAdenocarcinomaDeoxycytidinemedicine.drugmedicine.medical_specialtyanimal structures[SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/SurgeryAdenocarcinoma03 medical and health sciencesHepatic arterial infusionInternal medicinemedicineHumansInfusions Intra-Arterial030304 developmental biologyChemotherapybusiness.industrymedicine.diseaseGemcitabineGemcitabineOxaliplatinchemistrybusinessTomography X-Ray Computed
researchProduct

Safety of ninety-minute daratumumab infusion.

2020

Purpose Daratumumab is the first anti-CD38 monoclonal antibody of the class approved for recurrent and refractory multiple myeloma. Grade 3 and 4 Infusion-Related Reactions (IRRs) are frequent during the first and second infusions. Due to the risks associated with severe IRRs, daratumumab is systematically administered over a period of 3.5 hours. The main objective of this study was to evaluate the safety of a 90-minute daratumumab infusion from the third infusion. Patients and methods All patients who had received two or more doses of daratumumab in monotherapy or in combination with standard infusion rates were included. We excluded patients enrolled in clinical trials. For the rapid infu…

OncologyMalemedicine.medical_specialtymedicine.drug_classAntineoplastic AgentsInfusion related reactionMonoclonal antibody03 medical and health sciences0302 clinical medicineInternal medicineMedicineHumansPharmacology (medical)Infusions IntravenousMultiple myelomaAgedAged 80 and overbusiness.industryDaratumumabAntibodies MonoclonalRefractory Multiple MyelomaMiddle Agedmedicine.diseaseOncology030220 oncology & carcinogenesisFemalebusinessMultiple Myeloma030215 immunologyJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
researchProduct